Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma - Contacts and Locations

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

This study is currently recruiting participants.

Study NCT00450814. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00450814

Locations


United States, Minnesota
	Mayo Clinic Cancer Center	Recruiting
	Rochester, Minnesota, United States, 55905
	Contact: Clinical Trials Office - All Mayo Clinic Locations 507-538-7623

Sponsors and Collaborators

Mayo Clinic

National Cancer Institute (NCI)

Investigators


Study Chair:	Angela Dispenzieri, MD	Mayo Clinic

Investigator:	Morie A. Gertz, MD	Mayo Clinic

Investigator:	Philip R. Greipp, MD	Mayo Clinic

Investigator:	Robert A. Kyle, MD	Mayo Clinic

Investigator:	Martha Q. Lacy, MD	Mayo Clinic

Investigator:	John A. Lust, MD, PhD	Mayo Clinic

Investigator:	S. V. Rajkumar, MD	Mayo Clinic

Investigator:	Thomas E. Witzig, MD	Mayo Clinic

Investigator:	Steve Zeldenrust, MD	Mayo Clinic

Investigator:	Shaji K. Kumar, MD	Mayo Clinic

Investigator:	Gregory Wiseman, MD	Mayo Clinic

Investigator:	Suzanne Hayman, MD	Mayo Clinic

Investigator:	Stephen J. Russell, MD, PhD	Mayo Clinic

Investigator:	Raymund Razonable, MD	Mayo Clinic